Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ride the Tiger with CD -- Ignore unavailable to you. Want to Upgrade?

To: Cheeky Kid who wrote (175042)	9/24/2009 9:46:36 AM
From: Philip Nolan	Read Replies (1) \| Respond to of 313051

ENW News "ENW looking interesting, little worried about investing in an area I know nothing about. Stocks at 52 weeks high. I will track it to see how it trades. " As I said earlier, I'm not sure that this will be a trading stock but the potential of what they are developing seems incredible. The same institutional broker that brought Sensio around to its clients and launched it is getting behind Enwave. Full disclosure, I've built up a large position and will be holding for multiple dollars. TSX Venture Exchange trading symbol: ENW www.enwave.net EnWave Announces Successful Test Results for Antibodies Using freezeREV Dehydration Technology Vancouver, B.C., September 24, 2009 EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has successfully dried three different antibodies in the Company’s prototype freezeREV vial dehydration technology. Results from this study showed no detectable visual difference between freezeREV-dried and freeze dried samples when examined with the SDS-PAGE electrophoresis method. Additionally, the indication of the molecular weight was similar between the two dried samples and liquid antibodies. The current industry process of freeze drying, or lyophilization, can be particularly harsh on sensitive materials such as antibodies because of the length of time that organisms are exposed to extremely low temperatures. The freezeREV prototype has been designed to significantly reduce the drying time and temperature exposure from days, to minutes or hours, creating the potential for a high-speed, cost effective dehydration technology. The Company believes that a commercial-scale freezeREV machine could reduce the costs of dehydration for live or active pharmaceuticals and reagents by as much as 80%. “These are exciting results for the company as we are seeing the potential of this technology in a new area of biopharmaceuticals and biomaterials” said Dr. Durance. “We have tested a variety of proteins in the past, but antibody dehydration could open up a huge new market for EnWave, and this would compliment our existing research into vaccine dehydration.” The three polyclonal antibodies used in this study were derived from chicken, rabbit and bovine blood serum, and are used by the pharmaceutical industry for drug research. They are also used in the production of animal vaccines, and as feed additives to improve animal health. Dehydration of antibodies is important to the pharmaceutical and biotechnology sectors, primarily because the process increases the shelf-life of these expensive and difficult-to-manufacture organisms. Antibodies are infection fighting proteins used in a wide variety of applications including medical research and diagnostics, prenatal therapy, and treatment of diseases such as cancer, heart disease, rheumatoid arthritis and multiple sclerosis. freezeREV is a dehydration method for biomaterials in vials where low moisture levels in the final product are imperative for long product shelf-life. This technology is being designed to create room temperature stable pharmaceuticals or reagents containing live organisms such as viruses, bacteria and antibodies where an emphasis must be placed on maintaining the maximum possible survival rates of these organisms until they are delivered to a patient. EnWave has initiated a search for a major industry partner with whom to expand testing for both polyclonal and monoclonal antibody products with the goal of proving that freezeREV dehydration technology can be developed into a commercially viable method. About EnWave Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating food and biological materials using Radiant Energy Vacuum technology under its nutraREVTM, powderREV, bioREVTM and freezeREV brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net. EnWave Corporation Dr. Tim Durance Chairman & Co-CEO -end- For further information: Mr. John McNicol President & Co-CEO (604) 601-8524 john.mcnicol@enwave.net Jennifer Thompson, V.P. Corporate Development & Investor Relations (604) 603-6549 jthompson@enwave.net This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company’s REV technology can or will improve dehydration processes in the target industries; even if the Company’s REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company’s REV technology. The TSX Venture Exchange has neither approved nor disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.